4-氯-7-氟-喹啉-3-甲腈 | 622369-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-7-氟-喹啉-3-甲腈
• 英文名称: 4-chloro-7-fluoro-3-quinolinecarbonitrile
• 英文别名: 4-chloro-7-fluoroquinoline-3-carbonitrile
• CAS: 622369-70-4
• 化学式: C₁₀H₄ClFN₂
• 分子量: 206.607
• InChiKey: GLDPOBFSPURDRC-UHFFFAOYSA-N

物化性质

• 沸点：
  351.7±37.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  4-氯-7-氟-喹啉-3-甲腈 、 2,4-二氯-5-甲氧基苯胺 在 吡啶盐酸盐 作用下， 以 乙二醇乙醚 为溶剂， 反应 3.0h， 以48%的产率得到4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-fluoro-3-quinolinecarbonitrile
  参考文献：
  名称：

  Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: Identification of potent 7-amino analogs

  摘要：

  A more efficient preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-fluoro-6-methoxy-3-quinolinecarbonitrile (2), the penultimate intermediate in the synthesis of bosutinib (1a), was developed. New 7-alkoxy-4-phenylamino-3-quinolinecarbonitrile Src inhibitors were prepared from 5 and 9, the 6-ethoxy and 6-hydrogen analogs of 2. In addition, the fluoro group of 2 was readily displaced by primary and secondary amines to give 7-amino analogs. Two of these 7-amino analogs, 15 and 18, were potent Src inhibitors with in vivo activity. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.09.028
• 作为产物：
  描述：

  7-氟-4-氧代-1,4-二氢-3-喹啉腈 在 N,N-二甲基甲酰胺 氯化亚砜 作用下， 反应 1.5h， 生成 4-氯-7-氟-喹啉-3-甲腈
  参考文献：
  名称：

  Process for the preparation of 7-substituted-3 quinolinecarbonitriles

  摘要：

  提供了一种制备7-取代-3-喹啉羰基腈和中间体的方法，该中间体在制备7-取代-3-喹啉羰基腈和药用可接受盐的过程中有用。将7-氟-4-氧代-1,4-二氢-3-喹啉羰基腈转化为7-取代-3-喹啉羰基腈，经过三个步骤，这些化合物抑制某些蛋白激酶的作用，并在癌症治疗中有用。

  公开号：

  US20030212276A1

文献信息

• [EN] COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE<br/>[FR] COMPOSÉS UTILES POUR MODIFIER LES TAUX D'ACIDES BILIAIRES POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES CARDIOMÉTABOLIQUES.
  申请人：MERCK SHARP & DOHME

  公开号：WO2018034918A1

  公开（公告）日：2018-02-22

  Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

  本文描述了式（I）的化合物或其药用可接受的盐。式（I）的化合物作为Cyp8b1抑制剂，可用于预防、治疗或作为糖尿病和心血管疾病的治疗剂。
• Process for the preparation of 7-substituted-3 quinolinecarbonitriles
  申请人：Wyeth Holdings Corporation

  公开号：US20030212276A1

  公开（公告）日：2003-11-13

  There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.

  提供了一种制备7-取代-3-喹啉羰基腈和中间体的方法，该中间体在制备7-取代-3-喹啉羰基腈和药用可接受盐的过程中有用。将7-氟-4-氧代-1,4-二氢-3-喹啉羰基腈转化为7-取代-3-喹啉羰基腈，经过三个步骤，这些化合物抑制某些蛋白激酶的作用，并在癌症治疗中有用。
• [EN] IMINO SULFANONE INHIBITORS OF ENPP1<br/>[FR] INHIBITEURS IMINO SULFANONE DE L'ENPP1
  申请人：VOLASTRA THERAPEUTICS INC

  公开号：WO2021225969A1

  公开（公告）日：2021-11-11

  The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

  本公开涉及一般来说是对细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的抑制剂，其组合物以及使用所述化合物和组合物的方法。更具体地说，本公开涉及基于砜亚胺的ENPP1抑制剂，其化学式为（I），以及其用于治疗由ENPP1介导的疾病的方法。
• 3-Quinolinecarbonitrile protein kinase inhibitors
  申请人：Berger Maarten Dan

  公开号：US20050187247A1

  公开（公告）日：2005-08-25

  This invention provides a compound of Formula 1 where Ar, X, R 1 , R 2 , R 3 , and R 4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

  该发明提供了一种化合物，其化学式为1，其中Ar、X、R1、R2、R3和R4的定义如下，或其药用盐，在哺乳动物体内用于预防或抑制与Ras/Raf/MEK信号级联相关的疾病，如肿瘤、中风、骨质疏松症、癌症、类风湿性关节炎、炎症性疾病、多囊性肾病和结肠息肉，以及制备化合物1和中间体的方法。
• [EN] PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES<br/>[FR] PREPARATION DE 3-QUINOLINE ET DE 3-QUINOL- 4-ONE CARBONITRILES SUBSTITUES EN POSITION 7
  申请人：WYETH CORP

  公开号：WO2003093241A1

  公开（公告）日：2003-11-13

  There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.

  提供了一种制备7-取代-3-喹啉羰基腈及其中间体的方法，该中间体可用于制备7-取代-3-喹啉羰基腈及其药用可接受盐的方法。其中，7-氟-4-氧代-1,4-二氢-3-喹啉羰基腈经过三步转化成为抑制某些蛋白激酶作用且用于治疗癌症的7-取代-3-喹啉羰基腈。